Drug intelligence / Profile preview

RetroVirox HIV Nef inhibitors

Development stage: Preclinical
Lead developer: RetroVirox
Modality: Small Molecules

Overview

RetroVirox is developing small molecule inhibitors that target the HIV Nef protein to prevent the downmodulation of MHC class I (MHC-I) molecules on the surface of infected T cells. By blocking this Nef-mediated immune evasion mechanism, the inhibitors restore the presentation of viral antigens, allowing cytotoxic T lymphocytes (CTLs) to recognize and kill HIV-infected cells. This therapeutic approach is designed to be a critical 'kill' component of 'kick and kill' HIV eradication strategies, aimed at eliminating the latent viral reservoir. The program is currently in the preclinical stage, with lead compounds demonstrating high potency and selectivity.

Other names: HIV Immunomodulatorsunnamed lead inhibitors

Targets

Nef (HIV-1 Nef)

Beyond the preview

Go deeper on RetroVirox HIV Nef inhibitors.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RetroVirox HIV Nef inhibitors.

Explore the full profile